Myungin announced on the 22nd that it has signed a license and investment contract with Israeli pharmaceutical company Pharma Two B (P2B) for commercialization of Parkinson's disease treatment in Korea.

P2B001, which is being developed by P2B, is a new combination of low-dose sustained-release drug Rasagilin and sustained-release drug Pramipexole, which is widely used for Parkinson's disease. It is manufactured to solve unmet demand while minimizing side effects by combining two drugs that act as different pharmacological mechanisms. P2B001 is taken only once a day, and dose control is not required.

P2B completed multinational phase 3 clinical trials of P2B001 in 70 regions of North Ameri